Contact
searchSearch
HMP Global

Biosimilars

Featured Article

Conference Coverage
Real-World Strategies for Implementing Biosimilars
04/12/2023
Hannah Musick
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed the current landscape of biosimilars from a payer perspective as well as lessons learned from health system biosimilar adoption. 
Speakers at AMCP 2023 discussed...
04/12/2023
First Report Managed Care
From First Report Managed Care
Conference Insider
Addressing and Understanding Challenges Linked With Adopting Biosimilars Into Practice
12/08/2020
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear 2020, Osama Abdelghany, PharmD, MHA, BCOP Yale New Haven Hospital, and David L Crosby, PharmD, BCOP, BCPS, Dartmouth-Hitchcock Health, provide a variety of clinical, operational, and payer coverage considerations...
In a session at ASHP Midyear...
12/08/2020
Pharmacy Learning Network
Quiz
Identifying Pharmacist Knowledge of a Medication Drug Type
11/24/2020
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data, pharmacists are more well-informed about which medication type—with more than 80% demonstrating solid knowledge of their safety, efficacy, compatibility, and costs?
Based on recent data,...
11/24/2020
Pharmacy Learning Network
News
Most Pharmacists Show Good Grasp of Biosimilar Medications, Study Finds
11/20/2020
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug experts, need to be well aware of the applied handling of biosimilar medicines,” researchers wrote. “They are an integral educator, trailblazer, and advocate of biosimilar integration across all clinical settings.”
“Pharmacists, being the drug...
11/20/2020
Pharmacy Learning Network
Newsfeed
Biosimilar Infliximab Appears Effective in Crohn`s Disease
12/11/2018
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears to be safe and effective in infliximab-naive patients with Crohn's disease, according to a recent study.
An infliximab biosimilar appears...
12/11/2018
Pharmacy Learning Network
News
Etanercept Biosimilar is Effective, Well-Tolerated for Rheumatoid Arthritis
02/16/2018
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the efficacy of a biosimilar for treating patients with rheumatoid arthritis who respond inadequately to methotrexate
A recent study examined the...
02/16/2018
Pharmacy Learning Network
News
Biosimilar Infliximab Appears Safe, Effective in IBD Patients
12/15/2017
Researchers examined the effectiveness of switching to a biosimilar version of a drug in patients with IBD. 
Researchers examined the effectiveness of switching to a biosimilar version of a drug in patients with IBD. 
Researchers examined the...
12/15/2017
Pharmacy Learning Network
News
Pharmacist Role in Promoting Proper Biosimilar Usage
12/14/2017
Evelyn Hermes-Desantis, PharmD, BCPS, recently discussed the many factors involved in managing biosimilars in the hospital setting and the role pharmacists play in promoting their appropriate use in the context of safe patient care.
Evelyn Hermes-Desantis, PharmD, BCPS, recently discussed the many factors involved in managing biosimilars in the hospital setting and the role pharmacists play in promoting their appropriate use in the context of safe patient care.
Evelyn Hermes-Desantis, PharmD,...
12/14/2017
Pharmacy Learning Network
News
FDA Approves Another Biosimilar for RA Drug
12/14/2017
The FDA has approved a biosimilar for multiple autoimmune diseases. 
The FDA has approved a biosimilar for multiple autoimmune diseases. 
The FDA has approved a...
12/14/2017
Pharmacy Learning Network
News
FDA Approves First Biosimilar for Breast, Stomach Cancer
12/01/2017
The FDA has approved a biosimilar for two types of cancer.
The FDA has approved a biosimilar for two types of cancer.
The FDA has approved a...
12/01/2017
Pharmacy Learning Network
News
The Challenges of Bringing Biosimilars to Market
11/21/2017
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, explains how industry experts can help bring biosimilars to the market faster.
Edward Li, Pharm D, MPH, BCOP, a professor in the Department of Pharmacy Practice at the University of New England College of Pharmacy, explains how industry experts can help bring biosimilars to the market faster.
Edward Li, Pharm D, MPH, BCOP, a...
11/21/2017
Pharmacy Learning Network

Newsfeed

News
Communication Needed to Improve Biosimilar Transition, Adherence
10/19/2017
Patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months, a study showed. 
Patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months, a study showed. 
Patients with rheumatoid...
10/19/2017
Pharmacy Learning Network
News
FDA Approves Amgen`s Cheaper Copy of Arthritis Drug Humira
09/23/2016
The FDA has approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The FDA has approved a cheaper, biosimilar version of AbbVie's top-selling arthritis drug, Humira.
The FDA has approved a cheaper,...
09/23/2016
Pharmacy Learning Network
News
Novartis Biosimilar Takes Aim at Amgen`s Enbrel
10/23/2015
The FDA has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said.
The FDA has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster anti-TNF drug Enbrel, the Swiss drugmaker said.
The FDA has accepted Novartis...
10/23/2015
Pharmacy Learning Network
News
FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
08/28/2015
The FDA proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts.
The FDA proposed on Thursday identifying cheaper versions of biologic drugs with a suffix to distinguish them from their more expensive, branded counterparts.
The FDA proposed on Thursday...
08/28/2015
Pharmacy Learning Network
News
Dopamine Hydrochloride Injection Recalled Due to Lack of Sterility Assurance
09/24/2026
Rebecca Amrick
Dopamine hydrochloride injection is under a voluntary Class II recall due to the product’s lack of sterility assurance.
Dopamine hydrochloride injection is under a voluntary Class II recall due to the product’s lack of sterility assurance.
Dopamine hydrochloride injection...
09/24/2026
Pharmacy Learning Network
News
Chlorthalidone Tablets Recalled Due to Failed Dissolution Specifications
09/24/2026
Rebecca Amrick
A voluntary Class II recall has been issued for chlorthalidone tablets after the product failed to meet dissolution specifications, a discrepancy that affects 13 567 bottles.
A voluntary Class II recall has been issued for chlorthalidone tablets after the product failed to meet dissolution specifications, a discrepancy that affects 13 567 bottles.
A voluntary Class II recall has...
09/24/2026
Pharmacy Learning Network
News
Thyroid Tablets Recalled Due to Drug Superpotency
09/24/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for thyroid tablets due to drug superpotency, affecting 1955 bottles.
The US Food and Drug Administration (FDA) has issued a Class I recall for thyroid tablets due to drug superpotency, affecting 1955 bottles.
The US Food and Drug...
09/24/2026
Pharmacy Learning Network
PharmLaw
Express Scripts Faces Lawsuit Over Arkansas Pharmacy Reimbursement Rates
09/23/2026
Grace Taylor, MS, MA
Arkansas pharmacies allege Express Scripts violated state law by reimbursing prescription claims below required rates.
Arkansas pharmacies allege Express Scripts violated state law by reimbursing prescription claims below required rates.
Arkansas pharmacies allege...
09/23/2026
Pharmacy Learning Network
News
Povidone and Proparacaine Ophthalmic Solution Recalled Due to Drug Subpotency
09/17/2026
Rebecca Amrick
Povidone iodine and proparacaine hydrochloride ophthalmic solution is under a voluntary Class III recall due to drug subpotency, affecting 772 bottles.
Povidone iodine and proparacaine hydrochloride ophthalmic solution is under a voluntary Class III recall due to drug subpotency, affecting 772 bottles.
Povidone iodine and proparacaine...
09/17/2026
Pharmacy Learning Network
News
Fluphenazine Hydrochloride Tablets Recalled Due to Failed Impurities Specifications
09/17/2026
Rebecca Amrick
A voluntary Class III recall has been issued for fluphenazine hydrochloride tablets after the product failed to meet impurities specifications, a discrepancy that affects 403 200 tablets.
A voluntary Class III recall has been issued for fluphenazine hydrochloride tablets after the product failed to meet impurities specifications, a discrepancy that affects 403 200 tablets.
A voluntary Class III recall has...
09/17/2026
Pharmacy Learning Network
News
Dextrose Injection Recalled Due to the Presence of Stainless Steel Particles
09/17/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) has issued a Class I recall for dextrose injection due to the presence of stainless steel particles in the product, affecting 606 bags.
The US Food and Drug Administration (FDA) has issued a Class I recall for dextrose injection due to the presence of stainless steel particles in the product, affecting 606 bags.
The US Food and Drug...
09/17/2026
Pharmacy Learning Network
PharmLaw
Dompé to Pay $32 Million Over Patient Assistance Foundation Kickback Allegations
09/16/2026
Hannah Musick
Dompé U.S. has agreed to pay $32 million to resolve allegations involving Medicare copay assistance for Oxervate, highlighting Anti-Kickback Statute compliance risks associated with manufacturer-funded patient assistance programs and the...
Dompé U.S. has agreed to pay $32 million to resolve allegations involving Medicare copay assistance for Oxervate, highlighting Anti-Kickback Statute compliance risks associated with manufacturer-funded patient assistance programs and the...
Dompé U.S. has agreed to pay $32...
09/16/2026
Pharmacy Learning Network
News
Topiramate Capsules Recalled Due to Failed Dissolution Specifications
09/10/2026
Rebecca Amrick
Trokendi (topiramate) extended-release capsules are under a voluntary Class III recall due to failed dissolution specifications, affecting 11 304 bottles.
Trokendi (topiramate) extended-release capsules are under a voluntary Class III recall due to failed dissolution specifications, affecting 11 304 bottles.
Trokendi (topiramate)...
09/10/2026
Pharmacy Learning Network
News
Trazodone Hydrochloride Tablets Recalled Due to the Presence of Foreign Tablets
09/10/2026
Rebecca Amrick
A voluntary Class II recall has been issued for trazodone hydrochloride tablets after the firm discovered foreign tablets in the product, a discrepancy that affects 175 392 bottles.
A voluntary Class II recall has been issued for trazodone hydrochloride tablets after the firm discovered foreign tablets in the product, a discrepancy that affects 175 392 bottles.
A voluntary Class II recall has...
09/10/2026
Pharmacy Learning Network

Insights

Interactive Features

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use